| Title: |
IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia |
| Authors: |
Sydney Dunn-Valadez, Srilakshmi Bathini, Carly Elston, Sravanti Rangaraju, Antonio Di Stasi, Sarah Worth, Diana Morlote, Shuko Harada, Pankit Vachhani |
| Source: |
Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100560- (2022) |
| Publisher Information: |
Elsevier, 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
IDH1, Ivosidenib, Differentiation syndrome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Ivosidenib is an oral inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). It is approved for treatment of patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) and patients with newly diagnosed IDH1-mutated AML who are 75 years or older or those who are ineligible to receive intensive chemotherapy. While generally well tolerated, differentiation syndrome has been reported in 15–20% of patients. Here, we report a case of acute febrile neutrophilic dermatosis or Sweet's syndrome in conjunction with the use of ivosidenib for the treatment of relapsed AML. We discuss the clinical presentation of this rare entity, review relevant literature, and comment on its association with differentiation syndrome. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2468-2942 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2468294222000508; https://doaj.org/toc/2468-2942 |
| DOI: |
10.1016/j.ctarc.2022.100560 |
| Access URL: |
https://doaj.org/article/2fa1bcd8c31444e0bc126a135dcd519a |
| Accession Number: |
edsdoj.2fa1bcd8c31444e0bc126a135dcd519a |
| Database: |
Directory of Open Access Journals |
